Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Elander, N Aughton, K Ghaneh, P Neoptolemos, J Palmer, D Cox, T Campbell, F Costello, E Halloran, C Mackey, J
Elander, N
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Citations
Altmetric:
Abstract
Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy.
Authors
Elander, N
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Aughton, K
Ghaneh, P
Neoptolemos, J
Palmer, D
Cox, T
Campbell, F
Costello, E
Halloran, C
Mackey, J
Scarfe, A
Valle, Juan W
McDonald, A
Carter, R
Tebbutt, N
Goldstein, D
Shannon, J
Dervenis, C
Glimelius, B
Deakin, M
Charnley, R
Anthoney, A
Lerch, M
Mayerle, J
Oláh, A
Büchler, M
Greenhalf, W
Description
Date
2018-04
Publisher
Collections
Keywords
Type
Article
Citation
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. 2018, 118(7): 947-954 Br J Cancer